收费全文 | 9714篇 |
免费 | 723篇 |
国内免费 | 80篇 |
耳鼻咽喉 | 68篇 |
儿科学 | 239篇 |
妇产科学 | 72篇 |
基础医学 | 1084篇 |
口腔科学 | 199篇 |
临床医学 | 669篇 |
内科学 | 2773篇 |
皮肤病学 | 392篇 |
神经病学 | 697篇 |
特种医学 | 501篇 |
外科学 | 1642篇 |
综合类 | 46篇 |
一般理论 | 1篇 |
预防医学 | 232篇 |
眼科学 | 161篇 |
药学 | 541篇 |
中国医学 | 12篇 |
肿瘤学 | 1188篇 |
2023年 | 124篇 |
2022年 | 89篇 |
2021年 | 404篇 |
2020年 | 237篇 |
2019年 | 317篇 |
2018年 | 390篇 |
2017年 | 356篇 |
2016年 | 382篇 |
2015年 | 355篇 |
2014年 | 462篇 |
2013年 | 488篇 |
2012年 | 834篇 |
2011年 | 847篇 |
2010年 | 443篇 |
2009年 | 366篇 |
2008年 | 598篇 |
2007年 | 666篇 |
2006年 | 576篇 |
2005年 | 537篇 |
2004年 | 428篇 |
2003年 | 386篇 |
2002年 | 318篇 |
2001年 | 106篇 |
2000年 | 75篇 |
1999年 | 98篇 |
1998年 | 41篇 |
1997年 | 45篇 |
1996年 | 29篇 |
1995年 | 28篇 |
1994年 | 29篇 |
1993年 | 23篇 |
1992年 | 57篇 |
1991年 | 47篇 |
1990年 | 37篇 |
1989年 | 38篇 |
1988年 | 25篇 |
1987年 | 16篇 |
1986年 | 25篇 |
1985年 | 41篇 |
1984年 | 27篇 |
1983年 | 19篇 |
1982年 | 7篇 |
1981年 | 8篇 |
1980年 | 10篇 |
1979年 | 7篇 |
1978年 | 9篇 |
1974年 | 7篇 |
1971年 | 6篇 |
1970年 | 7篇 |
1968年 | 7篇 |
Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its effectiveness and safety in patients with poor performance status (PS) are unknown.
MethodsEnrolled patients showed disease progression after treatment with gefitinib, erlotinib, or afatinib; T790M mutation; stage IIIB, IV, or recurrent disease; and PS of 2–4. Osimertinib was orally administered at a dose of 80 mg/day. The primary endpoint of this phase II study (registration, jRCTs061180018) was response rate and the secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate, and safety.
ResultsThirty-three patients were enrolled, of which 69.7% and 24.2% had PS of 2 and 3, respectively. One patient was excluded due to protocol violation; in the remaining 32 patients, the response rate was 53.1%; disease control rate was 75.0%; PFS was 5.1 months; and OS was 10.0 months. The most frequent adverse event of grade 3 or higher severity was lymphopenia (12.1%). Interstitial lung disease (ILD) was observed at all grades and at grades 3–5 in 15.2% (5/33) and 6.1% (2/33) of patients, respectively. Treatment-related death due to ILD occurred in one patient. Patients negative for activating EGFR mutations after osimertinib administration had longer median PFS than those positive for these mutations.
ConclusionOsimertinib was sufficiently effective in EGFR-TKI-resistant, poor PS patients with T790M mutation-positive advanced NSCLC. Plasma EGFR mutation clearance after TKI treatment could predict the response to EGFR-TKIs.
相似文献Methods: Twenty patients who underwent MPFL reconstruction for unilateral recurrent patellar dislocation (18 females and 2 males; mean age 20.8 ± 7.6 years) were examined. The peak isometric torque at 60° and 90° of knee flexion and isokinetic knee extensor strength at speeds of 60°/s and 90°/s in operated and non-operated legs were measured using a dynamometer preoperatively and 6 months, 1 year, and 2 years postoperatively. The following parameters were evaluated: (1) body weight-adjusted muscle strength, (2) improvement index (post-/preoperative value × 100) (%), and (3) extensor strength ratio (operated/non-operated value × 100) (%).
Results: The mean knee extensor strength in both operated and non-operated legs significantly increased 2 years after surgery compared with that before surgery. At 2 years postoperatively, the improvement indexes of the isometric knee extensor strength at 60° and 90° and of the isokinetic knee extensor strength at 60°/s and 90°/s were 237%, 192%, 318%, and 186%, respectively, in the operated legs and 144%, 124%, 140%, and 140%, respectively, in the non-operated legs. At 2 years postoperatively, the mean isometric knee extensor strength ratios at 60° and 90° and the isokinetic knee extensor strength ratios at 60°/s and 180°/s were 81%, 84%, 81%, and 82%, respectively.
Conclusions: Knee extensor strength was improved in most patients after MPFL reconstruction, at least compared with that before surgery, although an approximately 20% deficit against the non-operated legs remained even 2 years after surgery. 相似文献